Basic Information
| LncRNA/CircRNA Name | OXCT1-AS1 |
| Synonyms | NA |
| Region | GRCh38_5:41870030-41872241 |
| Ensemble | ENSG00000248668 |
| Refseq | NR_046635 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, etc. |
| Sample | fresh surgical samples (BCa primary tumor tissues and metastatic lymph nodes), Human BCa cell lines T24, 5637, and EJ-M3 as well as normal epithelial cell line SVHUC-1 |
| Expression Pattern | up-regulated |
| Function Description | lncRNA OXCT1 AS1, which elevated in metastasis lymph node, was significantly upregulated in BCa cell lines compared with SVHUC 1. We demonstrated OXCT1 AS1 inhibited miR 455 5p to decrease its binding to the JAK1 3 untranslated region, which could upregulate the expression of JAK1 at the protein level, thus promoting BCa proliferation and invasion. Therefore, lncRNA OXCT1 AS1 could act as a potential biomarker and therapeutic target for patients with BCa. |
| Pubmed ID | 30609030 |
| Year | 2019 |
| Title | Microarray expression profiles analysis revealed lncRNA OXCT1-AS1 promoted bladder cancer cell aggressiveness via miR-455-5p/JAK1 signaling. |
External Links
| Links for OXCT1-AS1 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |